Cynvenio Biosystems, Inc. Announces New Data Describing Superior Utility Of Sequenced DNA From LiquidBiopsy® Tumor Cells vs Cell Free DNA To Be Presented At The American Association for Cancer Research 2014 Meeting

AACR Annual Meeting, April 5-9, 2014 – Cynvenio Biosystems, Inc., a molecular diagnostics company focused on transforming targeted cancer treatment, will present data that sequence analysis of DNA recovered from circulating tumor cells (CTCdna) outperforms cell free derived DNA (cfDNA) template from the same patient sample at the American Association for Cancer Research (AACR) Annual Meeting on April 7 in San Diego, Calif. The performance differences were noted in the significantly better detection of clinically relevant mutations from Cynvenio’s CTCdna obtained by LiquidBiopsy.

Help employers find you! Check out all the jobs and post your resume.